Bergamot Supplementation Lipid Profile Meta-analysis: What the Evidence Says

Quick Answer

Bergamot Supplementation Lipid Profile Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Obesity is a multifactorial disease defined as abnormal or excessive fat accumulation that presents a risk to health because it is a major risk factor for several noncommunicable diseases (NCDs), such as cardiovascular diseases, diabetes, and several types of cancer. [Pujia Carmelo (2026); evidence level 1]
• Furthermore, obesity and its associated health problems have a significant economic impact on the global healthcare system. [Pujia Carmelo (2026); evidence level 1]
• In addition to its essential oil, bergamot is a relevant source of polyphenols and flavonoids, including unique C-glycosyl flavonoids such as brutieridin and melitidin, which have been associated with cardiometabolic, antioxidant, and anti-inflammatory effects. [De Bruno Alessandra (2026); evidence level 3]
• Currently, most industrial residues are mainly destined for livestock feed or bioenergy production, despite evidence showing that bergamot pomace and peel-derived fractions exhibit high phenolic content and strong antioxidant activity, as assessed by commonly used spectrophotometric assays such as DPPH, ABTS, and FRAP. [De Bruno Alessandra (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For bergamot supplementation lipid profile meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Pujia Carmelo (2026). Effect of Citrus bergamia Supplementation on Body Composition in Humans: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. DOI: 10.1111/obr.70094. PMCID: PMC13243342. PMID: 41572527. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13243342/
• De Bruno Alessandra (2026). Green Recovery of Bioactive Compounds from Bergamot ( Citrus bergamia ) By-Products: Sustainable Extraction, Food Applications, and Health-Promoting Properties. DOI: 10.3390/foods15111955. PMCID: PMC13256202. PMID: 42279740. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13256202/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.